AAV Gene Therapy for Autosomal Recessive Deafness 9: A Single-Arm Trial

Investigators conducted a single-arm trial of adeno-associated virus (AAV)-OTOF gene therapy using the Anc80L65 capsid in ten participants with autosomal recessive deafness 9 aged 1.5 to 23.9 years at five sites in China.